TY  - CONF
AU  - Bujanda, L.
AU  - Lanas, Á.
AU  - Quintero, E.
AU  - Castells, A.
AU  - Sarasqueta, C.
AU  - Cubiella, J.
AU  - Hernandez, V.
AU  - Morillas, J.D.
AU  - Perez-Fernández, T.
AU  - Salas, D.
AU  - Andreu, M.
AU  - Carballo, F.
AU  - Bessa, X.
AU  - Cosme, A.
AU  - Jover, R.
T1  - Effect of aspirin and antiplatelet drugs on the outcome of the fecal immunochemical test
LA  - eng
PY  - 2013
SP  - 683
EP  - 689
T2  - Mayo Clinic Proceedings
SN  - 0025-6196
VL  - 88
IS  - 7
PB  - Elsevier Ltd
AB  - Objective: To evaluate the effect of aspirin and nonaspirin antiplatelet agents (NAAAs) on the performance of the fecal immunochemical test (FIT). Participants and Methods: We performed a post hoc analysis of results from a clinical trial that involved 28,696 asymptomatic average-risk men and women aged 50 to 69 years invited to participate in a colorectal cancer screening program with FIT between November 1, 2008, and June 31, 2011. Results: The test was returned by 6390 individuals (22.3%), of whom 5821 (91.1%) reported not using antiplatelet drugs (nonusers group) and 569 (8.9%) reported using these drugs at the time of testing (users group). The FIT result was positive in 48 of 569 users (8.4%) and 365 of 5821 nonusers (6.3%) (P=.05). A positive FIT result was found in 7.3% (28/384) of aspirin users, 7.1% (10/140) of NAAA users, and 22.2% (10/45) of those undergoing dual antiplatelet therapy (DAPT) (aspirin plus an NAAA). The DAPT subgroup had a significantly higher positive FIT rate than the nonuser group (odds ratio, 3.5; 95% CI, 1.7- 7.3; P<.05). The positive predictive value (PPV) for advanced neoplasia (AN) in nonusers was 50.4% vs 50.0% in users (P = .40). The PPV for AN was 57.0% in aspirin users, 30.0% in NAAA users, and 50.0% in DAPT users, without statistically significant differences between the user and nonuser groups. Conclusion: The use of DAPT increased the rate of positive FIT results. Use of aspirin, NAAAs, or both did not modify the PPV for AN in this population-based colorectal screening program. © 2013 Mayo Foundation for Medical Education and Research.
DO  - 10.1016/J.MAYOCP.2013.04.016
UR  - https://portalciencia.ull.es/documentos/5e3c390629995246bbf5f0e2
DP  - Dialnet - Portal de la Investigación
ER  -